Cell study · human MCF-7 breast cancer cells

Fragment 176-191 aided doxorubicin against MCF-7 breast cancer cells

Checked against the paper Cell studyPublished by PepVault

The takeaway

This paper is early lab and computer research on using Fragment 176-191 to help a chemotherapy drug act on breast cancer cells, not evidence about effects in people.

Kind
Cell study
Studied in
Human MCF-7 breast cancer cells
Published
2022
Journal
Drug Des Devel Ther

What they tested

The team tested whether adding Fragment 176-191 to chitosan nanoparticles loaded with the chemotherapy drug doxorubicin makes them work better against breast cancer cells than particles carrying doxorubicin alone.

How the study was done

A lab study that combined computer docking simulations (models of how molecules fit onto proteins) with a cell viability test in human MCF-7 breast cancer cells. It compared nanoparticles carrying both the peptide and doxorubicin against nanoparticles carrying doxorubicin only.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking Fragment 176-191? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In human MCF-7 breast cancer cells grown in the lab, the particles carrying both Fragment 176-191 and doxorubicin had stronger anti-proliferative activity, meaning they held back cell growth more, than particles with doxorubicin alone. In the computer simulations, adding the peptide pointed to stronger doxorubicin binding to several breast cancer protein targets. Lab measurements rated the size, size spread and surface charge of the dual-loaded particles as clinically favorable.

What it doesn’t show

This was work in one breast cancer cell line plus computer modeling, so it is not a result in animals or people. The cell test compared dual-loaded particles with doxorubicin-only particles, and the gain was a computer-predicted and lab-dish effect, not a measured treatment outcome.

The paper

Habibullah et al. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. Drug Des Devel Ther. 2022.

The compound

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking Fragment 176-191? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo